News

Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.

Piotr Woźniak, MD, PhD, shares real-world evidence on Artelac Complete in dry eye disease from EuDEC 2026 in Milan, Italy, including improvements in tear break-up time and Schirmer scores, perioperative and contact lens use patterns, and high eye care practitioner satisfaction.

A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.

Researchers assessed accommodative changes after foldable iris-fixated phakic IOL implantation for myopic astigmatism

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.

The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.

AI models predicting retinal function from OCT could transform geographic atrophy assessment in clinical care and trials

This is a promotional supplement commissioned by Roche Products Limited.

Two cases highlight the diagnostic challenges of Demodex blepharitis and underscore the unmet need for approved targeted therapies in the United Kingdom.

Utilize oral agents, diet and glucose monitoring systems when acting to preserve vision

NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.

A scoping review finds limited evidence on transition programmes for adolescents moving from paediatric to adult ophthalmology care

A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.

A sutureless amniotic membrane matrix achieved faster healing and lower costs than standard PED care in a two-centre NHS audit.

A retrospective study of 114 oculoplastic surgery patients found trehalose added to sodium hyaluronate improved tear break-up time, corneal staining, and meibomian gland loss compared with sodium hyaluronate alone, particularly after eyelid reconstruction.

For Jay S. Duker, MD, and Ramiro Ribeiro, MD, PhD, paths that began in clinical and academic medicine became the foundation for a different kind of work—leading drug development from the inside.

A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.

The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.

The CE-marked lens is being placed by selected surgeons across 6 European countries under a company-described early-access program

Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.

A balanced mix of AI-generated and smartphone-captured images eliminated the domain-specific failures seen with single-source training

The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.

Retina cells that sense light falter in Alzheimer’s, potentially derailing sleep and body clocks—pointing to new diagnostic and treatment angles.

Immediate flushing of the eye can significantly reduce long-term damage after chemical exposure

StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.